Breaking News, Collaborations & Alliances

Biocytogen, Myricx Enter ADC Option and License Agreement

Myricx will provide linker and payload and Biocytogen will use its RenMice-derived fully human antibodies to make ADCs.

Biocytogen Pharmaceuticals Co., Ltd., a global biotech company focusing on the discovery of antibody therapeutics, entered into an antibody evaluation, option and license agreement with Myricx Bio, a UK biotech company focusing on a completely novel class of selective cytotoxic payloads for antibody drug conjugates (ADCs). Myricx will provide its linker and payload and Biocytogen will conjugate them with its RenMice-derived fully human antibodies to make ADCs. Biocytogen will carry out feasib...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters